Health Condition 1: B078- Other viral warts
Conditions
Interventions
Intervention1: Intralesional BCG(Bacillus calmette-guerin)-Group B: Freeze-dried BCG will be reconstituted with 1ml of normal saline (diluent) using
sterile syringe and sterile needle . All the eligi
Sponsors
Jawaharlal Nehru Institute Of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1) Clinically diagnosed verruca vulgaris patients. 2) No concurrent treatment for verruca vulgaris.
Exclusion criteria
Exclusion criteria: 1) Patients with signs and symptoms of infection. 2) Pregnancy and lactation. 3) Age less than 12 years 4) Immunocompromised Individuals. 5) Patients with chronic disease. 6) Patients with a history of asthma and allergic skin disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients achieving complete clearance (100% on VAS) (primary binary outcome used for sample size), assessed at the scheduled follow-ups (treatment visits and final assessment).Timepoint: The proportion of patients achieving complete clearance (100% on VAS) (primary binary outcome used for sample size), assessed at the scheduled follow-ups (treatment visits and final assessment).-at 3,6,9 and 12weeks and 3months after last dose. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Incidence and severity of adverse effects.Timepoint: 1.Incidence and severity of adverse effects.-in weeks | — |
Countries
India
Contacts
Public ContactRavish Bhourya
Jawaharlal Nehru Institute Of Medical Sciences
Outcome results
None listed